A multicenter surveillance study of clinical Streptococcus isolates collected from 66 hospitals across China during 2021–2022 has found that antimicrobial resistance patterns differ sharply by bacterial species and by region, and that the choice of interpretive breakpoints can dramatically change how resistant a pathogen appears.
The researchers determined minimum inhibitory concentrations using broth microdilution and interpreted the results according to the CLSI M100 standard, 36th edition. Streptococcus agalactiae, also known as group B Streptococcus, and Streptococcus pneumoniae emerged as the predominant groups in the collection. Across the major species groups, beta-lactam antibiotics retained high activity against beta-hemolytic streptococci, but resistance to the older antimicrobial classes erythromycin, clindamycin, and tetracycline was frequent.
The species-specific numbers were striking. Group B Streptococcus showed resistance rates of 80.77 percent to erythromycin, 77.04 percent to clindamycin, and 64.66 percent to tetracycline. Viridans group streptococci displayed heterogeneous susceptibility profiles, with resistance patterns that varied among regions of the country.
Multidrug resistance phenotypes were common within individual species groups, and the study reported significant regional variation, particularly among group B Streptococcus isolates. The authors framed analyses involving small regional subgroups as exploratory, an important caveat given that differences in sampling intensity, patient populations, and local prescribing practices can all shape apparent geographic patterns. Even so, the findings suggest that national averages can mask meaningful local differences in which drugs are likely to fail.
The most consequential result concerns Streptococcus pneumoniae, where susceptibility classification depended strongly on which clinical breakpoint was applied. Among the same 413 non-meningitis isolates, penicillin resistance was 1.94 percent, or 8 of 413, when interpreted with non-meningitis breakpoints, but rose to 76.03 percent, or 314 of 413, when meningitis breakpoints were applied, a difference the authors report as statistically significant with P less than 0.0001. In practical terms, the same set of bacterial isolates could be described as almost fully susceptible or overwhelmingly resistant depending solely on the clinical context assumed for interpretation.
The study’s conclusion emphasizes that interpreting streptococcal resistance requires consideration of both the bacterial species and the clinical breakpoint scenario, since breakpoint selection may substantially influence categorical susceptibility classification.
The authors position clinically contextualized surveillance as a meaningful framework for monitoring antimicrobial resistance among streptococci. Rather than reporting a single resistance rate per drug, the approach separates isolates by species group, summarizes MIC50 and MIC90 values, tracks multidrug resistance phenotypes, and evaluates regional differences in both categorical resistance and full MIC distributions. For clinicians and stewardship programs, the practical message is twofold: macrolide, lincosamide, and tetracycline resistance is now widespread in group B Streptococcus in China, while beta-lactams remain reliable against the major beta-hemolytic species, and pneumococcal penicillin reports should always be read against the intended clinical scenario.
As with any surveillance study, the picture is a snapshot of isolates reaching participating laboratories rather than a population-based incidence survey, and the exploratory regional analyses should be confirmed with larger samples. The study was published as open access research on 26 October 2026.
Subject of Research: Multicenter surveillance of antimicrobial susceptibility and geographic variation among clinical Streptococcus isolates in China
Article Title: Multicenter surveillance of antimicrobial susceptibility profiles and geographic variation among Clinical Streptococcus isolates in China, 2021–2022
Article References: Wang, H., Yu, J., Zhang, G., Li, J., Zhang, J., Kang, W., Xu, Y., & Liu, Y. (2026). Multicenter surveillance of antimicrobial susceptibility profiles and geographic variation among Clinical Streptococcus isolates in China, 2021–2022. BMC Microbiology. https://doi.org/10.1186/s12866-026-05806-x
Image Credits: AI Generated
DOI: 10.1186/s12866-026-05806-x
Keywords: Streptococcus, antimicrobial resistance, surveillance, Streptococcus pneumoniae, group B Streptococcus, breakpoints, penicillin, erythromycin, clindamycin, China, multidrug resistance, MIC
News Source: Drew Townsend. (October 29, 2026). China-wide surveillance finds streptococcal resistance varies by species and breakpoint choice. Scienmag.
